ADS Biosystems Inc. focuses on novel approaches against cancer and metabolic diseases. We have established state-of-art platforms for early cancer detection with new cancer markers. ADS has also been working on potential therapeutics against SARS-CoV-2. Our quantitative ELISA kit detects RBD binding antibodies against RBD domain of spike protein of SARS-CoV-2 and has been verified with 31 recovered COVID-19 patients and healthy controls. We are now offering this kit commercially for research and development purposes in the fight against this pandemic. We have also developed a rabbit antibody against the RBD domain, which works both for Western blot analysis and ELISA.
We are looking forward to collaborating with you for the fight against COVID-19, cancer, and metabolic diseases.